NeurOp is a small biotechnology company that was founded to take advantage of the neurology and NMDA receptor expertise of its founders, Drs. Ray Dingledine, Jim McNamara and Steve Traynelis. The vision of the company is to discover and develop sub-type selective NMDA modulators that might applied clnically to a number of neurological and psychiatric conditions. NeurOp is presently focussed on the devlopement of NP10679, a GluN2B sub-type selective inhibitor of the NMDA receptor. Initial clnical studies are ongoing and phase I should be complete in 3AQ 2019. Pre-clinical data suggest that NP10679 might be useful in treating brain ischemia associated with stroke, head trauma and subarrachnoid hemmorhage, acute pain and nicotine craving.